(Q34224509)

31 July 2017

1 reference

title

Critical issues in the economic evaluation of interventions against communicable diseases (English)

1 reference

31 July 2017

Hutubessy RC

1

1 reference

31 July 2017

Bendib LM

series ordinal

2

1 reference

31 July 2017

Evans DB

series ordinal

3

1 reference

31 July 2017

publication date

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

78

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

191-206

1 reference

Economic analysis in randomized control trials

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Willingness to pay as a measure of health benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

7 January 2021

What Do Patients Value?

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The cost-effectiveness of permethrin impregnated bednets in preventing child mortality in Kassena-Nankana district of Northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Willingness to pay and the valuation of programmes for the prevention and control of influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Methodologic evaluation of the radiology cost-effectiveness literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic analyses of radiological procedures: a methodological evaluation of the medical literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Immunization programs and their costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic analysis at the global level: a resource requirement model for HIV prevention in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Extrapolation of cost-effectiveness information to local settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Health care contingent valuation studies: a review and classification of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Valuing the benefits of publicly-provided health care: does 'ability to pay' preclude the use of 'willingness to pay'?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Cost-effectiveness league tables: More harm than good?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The cost effectiveness of mass drug therapy for intestinal helminths

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Should governments subsidize the use of insecticide-impregnated mosquito nets in Africa? Implications of a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Willingness to pay. What's in a name?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The evidence base on the cost-effectiveness of malaria control measures in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Cost-effectiveness of malaria control in sub-Saharan Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Evaluating the cost-effectiveness of clinical and public health measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Economic considerations for helminth control

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Controlling schistosomiasis: the cost-effectiveness of alternative delivery strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Malaria epidemiology and economics: the effect of delayed immune acquisition on the cost-effectiveness of insecticide-treated bednets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Is vaccination against hepatitis B efficient? A review of world literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Methodological quality of economic modelling studies. A case study with hepatitis B vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

An exercise on the feasibility of carrying out secondary economic analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic evaluation in health care: is there a role for cost-benefit analysis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Willingness to pay for antihypertensive therapy--results of a Swedish pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economics, pharmaceuticals, and pharmacoeconomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Willingness to pay for reductions in angina pectoris attacks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic evaluation in schistosomiasis: using the Delphi technique to assess effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic evaluation in schistosomiasis: valuation of health states preferences. A research note

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The contingent valuation method in health care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Insecticide-treated bednets and curtains for preventing malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The generalisability of pharmacoeconomic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Modeling the impact of global tuberculosis control strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Development of WHO guidelines on generalized cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The willingness to pay for in vitro fertilization: a pilot study using contingent valuation

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Ghent International Working Group on Mother-to-Child Transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

A healthy body and a healthy mind?: the relationship between ill-health and cognitive function in school-age children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Trichuris trichiura infection and mental development in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Compliance and absenteeism in school children: implications for helminth control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Moderate to heavy infections ofTrichuris trichiuraaffect cognitive function in Jamaican school children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Parasitic helminth infection and cognitive function in school children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Evidence for an improvement in cognitive function following treatment of Schistosoma japonicum infection in Chinese primary schoolchildren.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis-endemic communities in Nigeria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Efficacy and effectiveness issues in the NIDA Cooperative Agreement: interventions for out-of-treatment drug users. National Institute on Drug Abuse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Evaluation of pharmacoeconomic studies: utilization of a checklist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Principles of economic analysis of health care technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Evidence for an association between hookworm infection and cognitive function in Indonesian school children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Pharmacoeconomics: state of the art in 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Affordability, cost-effectiveness and efficiency of primary health care: the Bamako Initiative experience in Benin and Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Oregon's Medicaid ranking and cost-effectiveness: is there any relationship?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Economic evaluation of parasitic diseases: a critique of the internal and external validity of published studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Poverty and mortality among the elderly: measurement of performance in 33 countries 1960-92.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-706X%2800%2900176-5

10.1016/S0001-706X(00)00176-5

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference